Logo

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity.

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity.

It all starts inside the cell...

1

2/3 of all proteins are inside our cells, including many key targets for disease pathways

2

Very few technologies are able to target specific tissues or specific cellular compartments. Edity can do both

3

Many of the most exciting therapeutic proteins (beyond antibodies) are limited by current delivery approaches

4

Immune cells can achieve deep tissue penetrance and can also recognize inflammatory signals from the body

5

Limits around tissue tropism, toxicity and payload size are major barriers in treating patients.  Immune cells overcome these issues

In nature, immune cells deliver a toxic payload to eliminate diseased cells

Dying_Cell

WE REDESIGN THE IMMUNE CELLS TO DELIVERY PROTEIN THERAPEUTICS INSTEAD​

This opens up a new universe of targets for treatment that have not previously been translated to the clinic

CureCell

Building the cure from the Inside out

We deliver proteins to cells anywhere in the body

Creating new modalities for intracellular therapy

ABOUT US

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.

The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function.  Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

Board

Eyal is a serial entrepreneur and has devoted the majority of his career to building medical device companies. He founded TopSpin medical, Pi-Cardia and Clear-Cut.

Eyal Kolka​

CO-FOUNDER, CHAIRMAN OF THE BOARD​

Graduate of the Weizmann Institute of Science, expert in gene editing and genetic screening, having spent 4 years at Emendo before founding Applied Genetics. Founded Edity in 2020.​​

Michal Golan-Mashiach
PhD, MBA

CO-FOUNDER AND CEO

Yoav is an experienced immunologist. He co-authored Edity’s core technology patent with Michal. Additionally, he is the co-founder and CEO Progenetics.

Yoav Manaster, PhD

CO-FOUNDER 

Omri is a General partner of NfX Bio. In addition to founding and selling his own company, C2i Genomics, he has helped fund and scale a number of exciting companies including Mammoth Biosciences and immunai.

Omri Amirav Drory

Board Member – NFX Bio

Executive Team

Graduate of the Weizmann Institute of Science, expert in gene editing and genetic screening, having spent 4 years at Emendo before founding Applied Genetics. Founded Edity in 2020.​​

Michal Golan-Mashiach
PhD, MBA

CO-FOUNDER AND CEO

Brian is a veteran of the gene editing field, having started with ZFNs before moving on to CRISPR and base editing at Horizon Discovery. He was instrumental in the sale of Horizon to PerkinElmer for $383M.

Brian Burke, PhD

CBO

Ofer is an expert in tumor immunology and has gained a strong industrial experience Compugen focusing on target validation of immuno-oncology programmes.

Ofer Levy, PhD

VP R&D

Sharon is an experienced biochemist and renowned oligo expert. At QBI, she headed the entire planning of pre-clinical studies, including in vitro and in vivo trials.

Sharon Avkin Nachum, PhD

VP TECHNOLOGY 

Assaf is an expert in CAR-T science and has had positions at the Weizmann Institute, UC Berkely and AbbVie. He is an inventor on one of the first allogeneic CAR T cell patents.

Assaf Marcus, PhD

VP TRANSLATIONAL SCIENCE

Investors

CONTACT US

+972-54-7414417
info@edity-tx.com
10 Menachem Plaut St.
7670609, Rehovot, IL